ΚΕΡΚΙΔΙΚΗ ΠΡΟΠΕΛΑΗ ΑΝΑΚΟΠΗΗ ΣΕΛΕΤΣΑΙΩΝ ΔΕΔΟΜΕΝΩΝ
|
|
- Oswin Harris
- 5 years ago
- Views:
Transcription
1 ΚΕΡΚΙΔΙΚΗ ΠΡΟΠΕΛΑΗ ΑΝΑΚΟΠΗΗ ΣΕΛΕΤΣΑΙΩΝ ΔΕΔΟΜΕΝΩΝ Dr ΝΙΚΟΛΑΟΣ ΚΑΥΚΑΣ MD, FESC Διεσθσνηής, Υπεύθσνος Αιμοδ/κού Εργαζηηρίοσ Καρδιολογική Κλινική Γεν. Νοζοκομείο Κ.Α.Τ.
2 OUTLINE Introduction Radial in the world Economics ppci and Radial Radiation and Radial Technical Issues Conclusions
3 OUTLINE Introduction Radial in the world Economics ppci and Radial Radiation and Radial Technical Issues Conclusions
4
5 Therapeutic Hypothesis in the Radial World Association Between Bleeding and Outcome in ACS and PCI Reducing bleeding improves outcome
6 Chatriwalla AK et al. JAMA 2013;
7
8 Site of Non-CABG Major Bleeds (RIVAL definition) *Sites of Non Access site Bleed: Gastrointestinal (most common site), ICH, Pericardial Tamponade and Other Jolly SS et al. Am Heart J. 2011;161:254-60
9
10 OUTLINE Introduction Radial in the world Economics ppci and Radial Radiation and Radial Technical Issues Conclusions
11 HISTORY of RADIAL APPROACH Rander 1948, radial cutdown 8-10F Campeau 1989, radial angiography Kiemeneij and Laarman, TR for stenting 1993 Technique has gained widespread acceptance
12
13 Caputo RP et al. Catheter Cardiovasc Interv. 2011;78:823-39
14
15
16
17
18
19
20
21
22
23
24
25
26 Cooper et al. Am Heart J 138;430,1999 Jolly et al. Lancet 2011
27 NY Times July 27, 2009
28
29 OUTLINE Introduction Radial in the world Economics ppci and Radial Radiation and Radial Technical Issues Conclusions
30
31
32
33
34
35
36
37
38
39
40
41
42 OUTLINE Introduction Radial in the world Economics ppci and Radial Radiation and Radial Technical Issues Conclusions
43 RIVAL Study Design NSTE-ACS and STEMI (n=7021) Key Inclusion: Intact dual circulation of hand required Interventionalist experienced with both (minimum 50 radial procedures in last year) Randomization Radial Access (n=3507) Femoral Access (n=3514) Blinded Adjudication of Outcomes Primary Outcome: Death, MI, stroke or non-cabg-related Major Bleeding at 30 days Jolly SS et al. Am Heart J. 2011;161:
44
45
46
47 Radial vs Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study F Principal investigators: E Romagnoli,G Biondi-Zoccai, G Sangiorgi, J Am Coll Cardiol 2012 Dec 18;60(24): R
48 RIFLE STEACS - flow chart Design 1001 patients enrolled between January 2009 and July 2011 in 4 clinical sites in Italy DESIGN: Prospective, randomized (1:1), parallel group, multi-center trial. INCLUSION CRITERIA: all ST Elevation Myocardial infarction (STEMI) eligible for primary percutaneous coronary intervention. ESCLUSION CRITERIA: contraindication to any of both percutaneous arterial access. international normalized ratio (INR) > 2.0. Femoral arm (N=501) Femoral arm (N=534) Clinical follow-up at 1 month in 100% Radial arm (N=500) Radial arm (N=467) Clinical follow-up at 1 month in 100% Intention-to-treat analysis
49 RIFLE STEACS results 30-day bleeding rate femoral arm radial arm p = p = p = % 47% 7.8% 6.8% 2.6% 5.4% 5.2% Bleedings Access site related Non access site related
50 RIFLE STEACS results 30-day MACCE rate p = femoral arm radial arm 9.2% 5.2% p = p = p = % 1.2% 1.8% 1.2% 0.6% 0.8% Cardiac death Myocardial Infarction Target Lesion Revascularization Cerebrovascular Accident
51
52
53 REDUCTION OF MORTALITY IN AMI USE OF CCU FIBRINOLYSIS PRIMARY PCI? PRIMARY PCI WITH RADIAL APPROACH
54
55 SAFARI-STEMI Trial
56
57
58 Radial and Women
59
60
61 OUTLINE Introduction Radial in the world Economics ppci and Radial Radiation and Radial Technical Issues Conclusions
62
63 EuroIntervention 2013;9: A review of radiation exposures associated with radial cardiac catheterisation 2013 EuroIntervention. All rights reserved.
64 EuroIntervention 2013;9: Radiation - the double-edged sword of interventional procedures 2013 EuroIntervention. All rights reserved.
65
66 EuroIntervention 2013;9: A review of radiation exposures associated with radial cardiac catheterisation 2013 EuroIntervention. All rights reserved.
67
68 EuroIntervention 2013;9: A review of radiation exposures associated with radial cardiac catheterisation 2013 EuroIntervention. All rights reserved.
69 EuroIntervention 2013;9: A review of radiation exposures associated with radial cardiac catheterisation 2013 EuroIntervention. All rights reserved.
70 JACC Vol. 55,No
71 EuroIntervention 2013;9: A review of radiation exposures associated with radial cardiac catheterisation 2013 EuroIntervention. All rights reserved.
72
73
74
75
76 Plourde G et al. AIM RADIAL 2013
77
78 EuroIntervention 2013;9: A novel lead attenuator to reduce operator exposure to scattered radiation in transradial coronary procedures 2013 EuroIntervention. All rights reserved.
79 EuroIntervention 2013;9: A novel lead attenuator to reduce operator exposure to scattered radiation in transradial coronary procedures 2013 EuroIntervention. All rights reserved.
80 EuroIntervention 2013;9: A review of radiation exposures associated with radial cardiac catheterisation 2013 EuroIntervention. All rights reserved.
81 EuroIntervention 2013;9: A review of radiation exposures associated with radial cardiac catheterisation 2013 EuroIntervention. All rights reserved.
82 OUTLINE Introduction Radial in the world Economics ppci and Radial Radiation and Radial Technical Issues Conclusions
83 Allen s Test
84
85
86 OCT Radial after sheath removal
87 OCT Radial after sheath removal of 2nd cath.
88
89
90
91
92
93 Introducers and Radial artery 6F in 82-92% of pts 7F in 57-77% of pts 8F in 25-65% of pts
94
95
96 Theory of Catheter Backup
97
98
99
100 Beyond the coronaries.
101
102
103 EuroIntervention 2010 Jun;6(2):240-6.
104 Κερκιδική Προζπέλαζη ζε Σύμπλοκες βλάβες Σηεθανιαίων αγγείων, ζε αζθενή με πρόζθαηο τειροσργηθέν ανεύρσζμα κοιλιακής αορηής Κασκάς Ν,.Μπάμπαλης Δ. ΕΚΕ 2011,52:124-8
105
106
107 ΤΧΝΟΣΗΣΑ ΑΙΣΙΑ ΚΑΙ ΠΡΟΒΛΕΠΣΙΚΟΙ ΠΑΡΑΓΟΝΣΕ ΑΠΟΣΤΧΙΑ ΚΕΡΚΙΔΙΚΗ ΠΡΟΠΕΛΑΗ ΕΝΔΕΙΞΗ ΚΑΘΕΣΗΡΙΑΜΟΤ Ο 55% ΛΟΙΠΑ 45% ΑΠΟΣΤΧΙΑ ΚΕΡΚΙΔΙΚΗ ΠΡΟΠΕΛΑΗ 5,9% Το υψηλότερο ποςοςτό αποτυχίασ κατεγράφη ςε γυναίκεσ>70 ετών και το μικρότερο ςε άνδρεσ< 70 ετών (10,9% ζναντι 5,8%) πασμός: 2,3% Ελικώσεις κερκιδικής: 1,3% Ελικώσεις Βραχ/λικού τελέχους: 1,2% Αποτυχία παρακέντησης: 0,7% Κακή στήριξη καθετήρα : 0,4%
108
109 CONCLUSIONS RADIAL APPROACH (-) (+)
110 FUTURE Studies involving transradial prosedures should focus on: Minimize radial artery injury Discover methods to reduce fluoroscopy times and radiation exposure Best practices for the application of transradial primary PCI
111 Σας Eυχαριστώ
112 EuroIntervention 2013;9: A novel lead attenuator to reduce operator exposure to scattered radiation in transradial coronary procedures 2013 EuroIntervention. All rights reserved.
113 EuroIntervention 2013;9: A review of radiation exposures associated with radial cardiac catheterisation 2013 EuroIntervention. All rights reserved.
114
115 Challenges during RA puncture
116
117
118
119 Risk of death (hazard Ratio) Procedure- and Non-Procedure-Related Bleeds are Associated with an higher 30-Day Mortality in NSTEMI N=26,452 ACS patients from GUSTO IIb, PURSUIT and PARAGON A & B Procedure-related GUSTO bleeds Non-procedure-related GUSTO bleeds None Mild Moderate Severe None Mild Moderate Severe Rao et al. Am J Cardiol 2005;96:
120 Other Outcomes Radial (n=3507) % Femoral (n=3514) % HR 95% CI P Major Vascular Access Site Complications Other Definitions of Major Bleeding TIMI Non-CABG Major Bleeding < ACUITY Non-CABG Major Bleeding* < * Post Hoc analysis
121 R I V A L Subgroups: Primary Outcome Death, MI, Stroke or non-cabg major Bleed Overall Age <75 75 Gender Female Male BMI < >35 Radial PCI Volume by Operator >142.5 Radial PCI Volume by Centre Lowest Tertile Middle Tertile Highest Tertile Diagnosis at presentation NSTE-ACS STEMI Radial better Femoral better Hazard Ratio (95% CI) p-value Interaction
122
ΓΙΑΚΔΡΚΙΓΙΚΗ ΠΡΟΠΔΛΑΗ ΚΑΙ ΑΓΓΔΙΟΠΛΑΣΙΚΗ: ΤΜΒΟΤΛΔ ΚΑΙ ΜΤΣΙΚΑ
ΓΙΑΚΔΡΚΙΓΙΚΗ ΠΡΟΠΔΛΑΗ ΚΑΙ ΑΓΓΔΙΟΠΛΑΣΙΚΗ: ΤΜΒΟΤΛΔ ΚΑΙ ΜΤΣΙΚΑ ΓΙΔΝΔΡΓΔΙΑ ΠΡΩΣΟΓΔΝΟΤ ΓΙΑΓΔΡΜΙΚΗ ΣΔΦΑΝΙΑΙΑ ΠΑΡΔΜΒΑΗ ΑΠΟ ΣΗΝ ΚΔΡΚΙΓΙΚΗ ΑΡΣΗΡΙΑ Λάμπρος Κ. Μόσιαλος Γιεσθσντής Δπεμβατικός Καρδιολόγος ΓΝΘ «Παπαγεωργίοσ»
More informationOverview of Trasradial Approach for Coronary Angiography and Intervention. A/Prof. Phạm Mạnh Hùng, MD.FACC., FESC
Overview of Trasradial Approach for Coronary Angiography and Intervention A/Prof. Phạm Mạnh Hùng, MD.FACC., FESC Outline Historical perspective and current trends Rationale for the radial approach Bleeding
More informationTransradial vs. Transfemoral Access in STEMI: Should We Randomize?
Transradial vs. Transfemoral Access in STEMI: Should We Randomize? Ajay J. Kirtane, MD, SM Center for Interventional Vascular Therapy Columbia University Medical Center / New York Presbyterian Hospital
More informationAccess Issues and Bleeding Complications
Cardiovascular Trends 2011: Nursing and Cath Lab Symposia ITS 2011 Access Issues and Bleeding Complications Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor
More informationTRANSRADIAL CARDIAC CATHETERIZATION. Amanda Ryan, DO, Interventional Cardiologist Heart Care Centers of Florida April 13, 2013
TRANSRADIAL CARDIAC CATHETERIZATION Amanda Ryan, DO, Interventional Cardiologist Heart Care Centers of Florida April 13, 2013 TOPICS Historical perspective and current trends Rationale Bleeding for the
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationSwitching from femoral to radial access for coronary angiography in ACS
ORIGINAL ARTICLE 169 Feasability, bleeding events and impact on door-to-balloon times Switching from femoral to radial access for coronary angiography in ACS Ivano Reho, Martin Sprenger, David Tueller,
More informationIs the role of bivalirudin established?
Is the role of bivalirudin established? Rob Henderson Consultant Cardiologist Trent Cardiac Centre Nottingham University Hospitals Conflicts of Interest: None Declarations: Member NICE Unstable Angina
More informationACUTE CORONARY SYNDROME PCI IN THE ELDERLY
ACUTE CORONARY SYNDROME PCI IN THE ELDERLY G.KARABELA MD.PhD ATHENS NAVAL HOSPITAL INTERVENTIONAL CARDIOLOGY DEPARTMENT NO CONFLICT OF INTEREST TO DECLAIRE Risk stratification in Αcute Coronary Syndrome.
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationLeft Main PCI vs. CABG: Real World
Management of Patients with Stable CAD Left Main PCI vs. CABG: Real World Marco Roffi, MD, FESC University Hospital Geneva, Switzerland SYNTAX-LMT The SYNTAX trial included a pre-specified subgroup of
More informationComparison of transradial and transfemoral approach for carotid artery stenting: RADCAR study
Comparison of transradial and transfemoral approach for carotid artery stenting: RADCAR study (RADial access for CARotide artery stenting) Zoltán Ruzsa MD PhD et al. TCT 2013 Disclosure Statement of Financial
More informationTransition from TF to TR Access in IO: Effect on Patient Radiation Exposure and Fluoroscopy Time
Transition from TF to TR Access in IO: Effect on Patient Radiation Exposure and Fluoroscopy Time Mircea Cristescu, Amanda Smolock, George Carberry, Prasad Dalvie, John Fallucca, Paul Laeseke, Orhan Ozkan,
More informationAsian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute
More informationΣτεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές
4 ο ΠΑΝΕΛΛΗΝΙΟ ΑΡΡΥΘΜΙΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ 21-22 ΣΕΠΤΕΜΒΡΙΟΥ 2018 HILTON, ΑΘΗΝΑ Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές Ι. Κανακάκης MD, PhD Διευθυντής Αιμοδυναμικού Τμήματος
More informationΠροβληματισμοι στην χρηση αντιαιμοπεταλιακων στα οξέα ισχαιμικά σύνδρομα
Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΚΑΙ ΟΜΩΝΥΜΟ ΕΡΓΑΣΤΗΡΙΟ ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΑΘΗΝΩΝ ΙΠΠΟΚΡΑΤΕΙΟ ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ Διευθυντής: Καθηγητής ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Προβληματισμοι στην χρηση αντιαιμοπεταλιακων
More informationΆγγελος Παπανικολάου MD, Ειδικευόμενος Καρδιολογίας, A Πανεπιστημιακή Καρδιολογική Κλινική, ΓΝΑ Ιπποκράτειο
Άγγελος Παπανικολάου MD, Ειδικευόμενος Καρδιολογίας, A Πανεπιστημιακή Καρδιολογική Κλινική, ΓΝΑ Ιπποκράτειο Endovascular access & closure Seldinger SI. Catheter replacement of the needle in percutaneous
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationFor Personal Use. Copyright HMP 2014
Radial Artery Intervention Operator and Institutional Experience Reduces Room-to-Balloon Times for Transradial Primary Percutaneous Coronary Intervention Kurt G. Barringhaus, MD, Mohammed Akhter, MD, Jeffrey
More informationBivalirudin should be indicated for all patients with STEMI. Adnan Kastrati Deutsches Herzzentrum, Munich, Germany
Bivalirudin should be indicated for all patients with STEMI Adnan Kastrati Deutsches Herzzentrum, Munich, Germany 1 Heparin+IIb/IIIa, heparin alone or bivalirudin in STEMI: Do we have the answer? 2 Heparin+IIb/IIIa,
More informationQuale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationRIVAL study: RadIal Vs. femoral access for coronary intervention in patients with acute coronary syndromes study. Sanjit Jolly MD, MSc FRCPC
RIVAL study: RadIal Vs. femoral access for coronary intervention in patients with acute coronary syndromes study Sanjit Jolly MD, MSc FRCPC Rationale Prior small trials and meta-analyses have demonstrated
More informationBivalirudin Clinical Trials Update Evidence and Future Perspectives
Bivalirudin Clinical Trials Update Evidence and Future Perspectives Andreas Baumbach Consultant Cardiologist/ hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol MY CONFLICTS
More informationCindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationCulprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
More informationSurgery Grand Rounds
Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationPERCUTANEOUS CORONARY INTERVENTION AND BLEEDING COMPLICATIONS
PERCUTANEOUS CORONARY INTERVENTION AND BLEEDING COMPLICATIONS *Sudhakar George, 1 Rob Butler, 1,2 James Nolan, 1,2 Mamas A. Mamas 1,2 1. Royal Stoke University Hospital, Stoke-on-Trent, UK 2. Keele Cardiovascular
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationCritics of Thrombolytics: Is Pre-Hospital Clot-busting Actually a Bad Thing? David Persse, MD Houston Fire Department EMS
Critics of Thrombolytics: Is Pre-Hospital Clot-busting Actually a Bad Thing? David Persse, MD Houston Fire Department EMS STEMI Stuff New or Recurrent MI s in U.S.: 865,000 Acute STEMI s: 500,000 Sooner
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationNeurologic complications after transradial or transfemoral approach for diagnostic and interventional cardiac catheterization.
Neurologic complications after transradial or transfemoral approach for diagnostic and interventional cardiac catheterization Dr Paolo Buja Trend Patients undergoing PCI in UK FEMORAL RADIAL Ratib JACC
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationThrombectomy. how? For whom?
Thrombectomy how? For whom? Marco Zimarino, MD, PhD Institute of Cardiology - University G. d Annunzio, Chieti (Italy) Why Manual Thrombectomy? Pros 1 Extraction of thrombotic material, acute reduction
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationTreatment of ST-elevation myocardial infarction in China: Where are we?
Treatment of ST-elevation myocardial infarction in China: Where are we? Associate Professor, Yihong Sun, MD Peking University People s Hospital Beijing, China Disclosure conflict of Interest The Challenges
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationRadial Artery Access Improving Outcomes and Decreasing Costs
Howard A. Cohen, MD, FACC, FSCAI Director, Division of Cardiac Intervention Co-Director, Cardiac Catheterization Laboratories Lenox Hill Heart & Vascular Institute Institute DISCLOSURE Nothing to disclose
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationApproach to Multi Vessel disease with STEMI
Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationIntroduction. Sho Torii 1 Toshiharu Fujii. Takeshi Ijichi 1 Masataka Nakano. Fuminobu Yoshimachi 1 Yuji Ikari
Cardiovasc Interv and Ther (2017) 32:114 119 DOI 10.1007/s12928-016-0395-z ORIGINAL ARTICLE Impact of a single universal guiding catheter on door-to-balloon time in primary transradial coronary intervention
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationParadigm Shift Updates on improving outcomes and reducing complications.
From Femoral to Radial: An Ongoing Paradigm Shift Updates on improving outcomes and reducing complications. By Rohan R. Wagle, MD, and Ralph Brindis, MD, MPH, MACC, FSCAI Percutaneous coronary intervention
More informationImportant Data Elements, Definitions and Metrics for Meaningful Results
Important Data Elements, Definitions and Metrics for Meaningful Results Roxana Mehran, MD Professor of Medicine (Cardiology) Director, Interventional Cardiovascular Research and Clinical Trials Mount Sinai
More informationΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Σημαντικές Εξελίξεις στη Θρόμβωση 2014 2015 TRA 2P TIMI 50 και TRACER Substudies ΚΑΛΑΝΤΖΗ ΚΑΛΛΙΡΡΟΗ Καρδιολόγος ιδάκτωρ Ιατρικής Σχολής Πανεπιστημίου
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationCritical Review Form Therapy Objectives: Methods:
Critical Review Form Therapy Clinical Trial Comparing Primary Coronary Angioplasty with Tissue-Plasminogen Activator for Acute Myocardial Infarction (GUSTO-IIb), NEJM 1997; 336: 1621-1628 Objectives: To
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationDr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου
Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Θεσσαλονίκη, 9/2/2018 Disclosures: None Primary efficacy outcome* (%/year) Antiplatelet Therapy
More informationIs there a real need for new agents to optimize efficacy/safety balance
Anticoagulation in acute coronary syndrome Is there a real need for new agents to optimize efficacy/safety balance Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationOBJECTIVES. New Twist To Old Disease: Cardiovascular Update /9/2017. Prevention Pre-operative Coronary Artery Disease
New Twist To Old Disease: Cardiovascular Update 2017 Sridevi R Pitta, M.D.,MBA, F.S.C.A.I., R.P.V.I Medical Director for STEMI, Medical Director for CV Quality Council, Interventional Cardiologist & Endovascular
More informationPost-Procedure Care and Same-Day PCI. Arnold Seto, MD, MPA
Post-Procedure Care and Same-Day PCI Arnold Seto, MD, MPA Post-Procedure Care Success of radial program depends upon effective access site management Training of staff critical to increase comfort with
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationTarget vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI
Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI Gamal Abdelhady, Emad Mahmoud Department of interventional
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationTrial Update- TOTAL. Jonathan Byrne
Trial Update- TOTAL Jonathan Byrne No conflicts of interest Background- rationale for thrombectomy Major Limitation of primary PCI: distal embolisation and reduced flow Stonel JACC 2002;39:591-7 Henriques
More informationCoronary angiography and PCI
Coronary arteries Coronary angiography and PCI Samo Granda, Franjo Naji Department of Cardiology Clinical department of internal medicine University clinical centre Maribor Coronary arteries Atherosclerosis
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationΣΥΜΠΛΟΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΔΙΧΑΣΜΩΝ
ΣΥΜΠΛΟΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΔΙΧΑΣΜΩΝ DR ΝΙΚΟΛΑΟΣ ΚΑΥΚΑΣ MD, FESC Διευθυντής, Υπεύθυνος Αιμοδ/κού Εργαστηρίου Καρδιολογική Κλινική Γεν. Νοσοκομείο ΚΑΤ-ΕΚΑ PCI in Coronary Bifurcations Bifurcations
More informationTransfemoral access (TFA) through the percutaneous
Transradial Coronary Intervention in STEMI Patients The current status of this approach and future perspectives on its staying power. By Simone Biscaglia, MD, and Marco Valgimigli, MD, PhD, FESC Transfemoral
More informationIs There A LIfe for DES after discontinuation of Clopidogrel
EMBARGOED UNTIL 3:45pm CT, Sunday, 11/16/14 - FOR MEDIA BACKGROUND ONLY - Do Not Publish Chicago 2014 Is There A LIfe for DES after discontinuation of Clopidogrel Six-month versus 24-month dual antiplatelet
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationINDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
More informationSurgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
More informationTransradial Artery Approach for Coronary Intervention: Maharat Nakhonratchasima Hospital Experience of The First 20 Cases
Transradial Artery Approach for Coronary Intervention: Maharat Nakhonratchasima Hospital Experience of The First 20 Cases Pinij Kaewsuwanna M.D. Tongprakob Siriwanij M.D. Cardiovascular Disease Center,
More informationΑντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)
Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο) Dimitrios Alexopoulos, MD, FESC, FACC Cardiology Department, Patras University Hospital, Patras, Rio, Greece. Patras University Hospital I, Dimitrios
More informationJun-Won Lee, Sang Wook Park, Jung-Woo Son, Young Jin Youn, Min-Soo Ahn, Sung Gyun Ahn, Jang-Young Kim, Byung-Soo Yoo, Junghan Yoon, Seung-Hwan Lee
The procedural success and complication rate of the left distal radial approach for coronary angiography and percutaneous coronary intervention. Prospective observational study (LeDRA) Jun-Won Lee, Sang
More informationPrimary PCI State of the Art. A/Prof Michael Nguyen Fremantle Hospital/Fiona Stanley Hospital Perth Australia JCR Meeting Busan 2014
Primary PCI State of the Art A/Prof Michael Nguyen Fremantle Hospital/Fiona Stanley Hospital Perth Australia JCR Meeting Busan 2014 Content Evidence of Primary PCI vs Thrombolysis When, Why, How Transfer
More informationManagement of Cardiogenic shock. Prof. Christian JM Vrints
Management of Cardiogenic shock Prof. Christian JM Vrints none conflicts Management of Cardiogenic Shock Incidence and trends Importance of early revascularization Multivessel disease Left main disease
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationRadial Artery Access: The Basics
Radial Artery Access: The Basics Jeffrey J. Popma, MD Professor of Medicine Harvard Medical School Director, Interventional Cardiology Beth Israel Deaconess Medical Center Boston, MA 1 Radial Artery Access:
More informationSTREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION. STREAM 1Y AHA 2013 P Sinnaeve
STREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION PCI Hospital Ambulance/ER STREAM design STEMI
More informationFFR in Multivessel Disease
FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationDR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI
The Impact of AF on Natural History of CAD DR ALEXIA STAVRATI CARDIOLOGIST, DIRECTOR OF CARDIOLOGY DEPT, "G. PAPANIKOLAOU" GH, THESSALONIKI CAD MOST COMMON CARDIOVASCULAR DISEASE MOST COMMON CAUSE OF DEATH
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationVascular Access: Management of Complications. Chris Burrell, South West Cardiothoracic Centre, Plymouth
Vascular Access: Management of Complications Chris Burrell, South West Cardiothoracic Centre, Plymouth Alternative Vascular Access Sites Femoral Axillary Brachial Radial Ulnar Femoral v Radial Vascular
More informationCPORT E Trial. Atlantic C PORT
CPORT E Trial Randomized trial comparing medical, economic and quality of life outcomes of non primary PCI at hospitals with and without on site cardiac surgery Mo#va#on for Trial Sustain primary PCI program
More informationMeet the Guidelines Le principali novità che modificheranno la nostra pratica clinica: STEMI
Meet the Guidelines 2017. Le principali novità che modificheranno la nostra pratica clinica: STEMI Guido Parodi Cardiologia Interventistica AOU Sassari Scuola di Specializzazione in Malattie dell Apparato
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Multivessel disease and cardiogenic shock: CABG is the optimal revascularization therapy. Contra Prof. Christian JM Vrints Cardiogenic Shock Spiral Acute Myocardial
More informationTim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute
Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute Implications of Pre-loading on Patients Undergoing Coronary Angiography Angiography Define
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More information